Influence of different prokinetic drugs on gastrointestinal transit times in patients with progressive-systemic sclerosis;Einfluss verschiedener prokinetika auf gastrointestinale transitzeiten bei patienten mit progressiv-systemischer sklerodermie

Zeitschrift fur Gastroenterologie

Volumn 35, Issue 10, 1997, Pages 905-912

  Folwaczny, C ^a   Laritz M ^a   Meurer, M ^a   Endres, S P ^a   Konig A ^a   Schindlbeck, N ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cisapride; Erythromycin; Intestinal transit disturbances; Lactulose H 2 breath test; Metal detector test; Octreotide; Progressive systemic sclerosis

Indexed keywords

CISAPRIDE; ERYTHROMYCIN; OCTREOTIDE; PROKINETIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL TRANSIT; HUMAN; INTESTINE TRANSIT TIME; MALE; ORAL DRUG ADMINISTRATION; STOMACH EMPTYING; SUBCUTANEOUS DRUG ADMINISTRATION; SYSTEMIC SCLEROSIS;

AGED; CISAPRIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROMYCIN; FEMALE; GASTRIC EMPTYING; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRANSIT; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; PIPERIDINES; SCLERODERMA, SYSTEMIC; SYMPATHOMIMETICS; TREATMENT OUTCOME;

EID: 0030817839     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994; 9: 1265-82
2. Folwaczny C, Voderholzer W, Riepl RL, Schindlbeck N. Klinik, Pathophysiologie. Diagnostik und Therapie gastrointestinaler Manifestationen der progressiv-systemischen Sklerodermic (PSS). Z Gastroenterol 1996; 34: 497-508
3. Di Marino JA, Carlson G, Myers A, Schumacher Rh, Cohen S. Duodenal myoelectric activity in scleroderma. N Engl J Med 1973; 289: 1220-3
4. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991; 21: 1461-7
5. Folwaczny C, Rothfuß U, Riepl RL et al. Gastrointestinale Beteiligung bei progressiv systemischer Sklerodermie (PSS). Z Gastroenterol 1995; 33: 654-61
6. Cohen S, Laufer I, Snape JW et al. The gastrointestinal manifestations of scleroderma: Pathogenesis and management. Gastroenterology 1980; 79: 155-66
7. Bluestone R, MacMahon M, Dawson JM. Systemic-sclerosis and small bowel involvement. Gut 1969; 10: 185-93
8. Hendel L, Hage E, Hendel J, Stentoft P. Omeprazole in the long-term treatment of severe gastroesophageal reflux disease in patients with systemic sclerosis. Aliment Pharmacol Ther 1992; 6: 565-77
9. Olive A, Maddison PJ, Davis M. Treatment of oesophagitis in scleroderma with omeprazole (letter). Br J Rheumatol 1989; 28: 553
10. Kaye SA, Lim SC, Taylor M et al. Small bowel bacterial overgrowth in systemic sclerosis: Detection using direct and indirect methods and treatment outcome. Br J Rheumatol 1995; 34: 265-9
11. Ewe K, Press AG, Dederer W. Gastrointestinal transit of undigestible solids measured by metal detector. Eur J Clin Invest 1989; 19: 291-7
12. Vantrappen G, Janssens J, Hellemans J, Ghoos Y. The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. J Clin Invest 1977; 59: 1158-66
13. Peeters TL, Janssens J, Vantrappen GR. Somatostatin and the interdigestive migrating motor complex in man. Regul Peptides 1983; 5: 209-17
14. Snape WJ, Matarazzo SA, Cohen S. Effect of eating and gastrointestinal hormones on human colonic motor activity. Gastroenterology 1978; 75: 373-8
15. Snape WJ, Wright SH, Battle WM, Cohen S. The gastrocolic response-evidence for a neuronal mechanism. Gastroenterology 1979; 77: 1235-40
16. Greenberger JN, Dobbins OW, Ruppert DR, Jesseph EJ. Intestinal atony in progressive systemic sclerosis (scleroderma). Am J Med 1968; 45: 301-8
17. Dewey MM. The anatomical basis of propagation in smooth muscle. Gastroenterology 1965; 49: 395
18. D'Angelo AW, Fries FJ, Masi TA, Shuman EL. Pathologic observations in systemic sclerosis (scleroderma). Am J Med 1969; 46: 428-40
19. Folwaczny C, Hundegger K, Volger C et al. Measurement of transit disorders in different gastrointestinal segments in patients with diabetes mellitus in relation to duration and severity of the disease by use of the metal detector test. Z Gastroenterol 1995; 33: 517-26
20. Maddern J, Horowitz M, Jamieson BC, Collins P, Roberts-Thomson P. Abnormalities of esophageal and gastric emptying in progressive systemic sclerosis. Gastroenterology 1984. 87; 4: 922-6
21. Kelly KA. Gastric emptying of liquids and solids: Roles of proximal and distal stomach. Am J Physiol 1980; 239: G71-6
22. Chiou AWH, Lin JK, Wang FM. Anorectal abnormalities in progressive sclerosis. Dis Colon Rectum 1989; 32: 417-21
23. Hamel-Roy J, Devroede G, Arhan P et al. Comparative esophageal and anorectal motility in scleroderma. Gastroenterology 1985; 88: 1-7
24. Nowak TV, Johnson CP, Kalbfleisch JH et al. Highly variable gastric emptying in patients with insulin-dependent diabetes mellitus. Gut 1995; 37: 23-9
25. Jian R, Ducrot F, Piedloup C et al. Measurement of gastric emptying in dyspeptic patients: Effect of a new gastrokinetic agent (cisapride). Gut 1985; 26: 352-8
26. Horowitz M, Maddern GJ, Maddox A et al. Effects of cisapride on gastric and esophageal emptying in progressive systemic sclerosis. Gastroenterology 1987; 93: 311-5
27. Janssens J, Peelers TL, Vantrappen G et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin: Preliminary studies. N Engl J Med 1990; 322: 1028-31
28. Dull JS, Rafuman J, Zakai MD, Strashun A, Straus EW. Successful treatment of gastroparesis with erythromycin in a patient with progressive systemic sclerosis. Am J Med 1990; 89: 528-30
29. Ueberschaer B, Ewe K, Alles U, Schmidtmann I. Effect of 4 × 250 mg erythromycin on human gastrointestinal transit. Z Gastroenterol 1995; 33: 340-4
30. Moller N, Petrany G, Cassidy D et al. Effects of the somatostatin analogue SMS 201-995 (sandostatin) on mouth-to-caecum transit time and absorption of fat and carbohydrates in normal man. Clin Science 1988; 75: 345-50
31. Compean DG, Jimenez JR, De La Garza FG et al. Octreotide therapy of large-volume refractory AIDS-associated diarrhea: A randomized clinical trial. AIDS 1994; 8: 1563-7